

IN THE UNITED STATES PATE	NT AND TRADEMARK OFFICE	o 🚍 '
Applicants: De Francesco et al.		0.5. PT 085476
Serial No.	Art Unit:	je979 10/
For: METHOD FOR REPRODUCING IN VITRO THE RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE ACTIVITIES ENCODED BY	Examiner:	

Assistant Commissioner for Patents Washington, D.C. 20231

HEPATITIS C VIRUS (HCV)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT Fcb 27, 2002
EXPRESS MAR NO. <u>\$4.523.911587.05</u>
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C., 20231.
MAILED BY Christie Chyfe
7 - 2 - 7 - 02

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

	MERCK	& CO., INC.	
			_
By		Date _	
	•		

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc. 07/31/2001





INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted or cited by the Office in a related application as follows:

	RELATED A	PPLICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
8/952,981	March 23, 1998	IT0002P
upon which the instant application relies for an earlier filing	date under 35 U.S.C. 120. Therefo	re, pursuant to
37 C.F.R. 1.98(d), copies of these references are not enclose	sed herewith. If this is inconvenient	, additional
copies will be submitted upon request.		

5. In accordance with 37 C.F.R. 1.97, (check one)

✓ the attached information is filed within three months of the filing date of the captioned case.

the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.

the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Respectfully submitted,

By: Sheldon O. Heber

Attorney For Applicant(s)

Reg. No. 38,179

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1958

Date: 2/27/67

-rease-typ	e a pius sign (+) liiside diis 00.	. —		SUBSTITUTE for PTO/SB/C* 208 00), Information Disclosure Statement by Applica Patent an ork Office; U.S DEPARTMENT OF COMMERC			
	Substitute for form 1449A/PTO				COMPLE F KNOWN		
INFORMATION DISCLOSURE		Application Number		0 =			
STATEMENT BY APPLICANT		Filing Date		P1 91			
		First Named Inventor	De Francesco et al.	.S.			
	,		,	Group Art Unit		20/00/25/25/25/25/25/25/25/25/25/25/25/25/25/	
	(use as many she	ets as r	iecessary)	Examiner Name		10	
Shee	t 1	of	2	Attorney Docket Number	IT0002PCA		

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY
		5,981,247		Emory University	11/09/1999

	FOREIGN PATENT DOCUMENTS					
-	0:1-		Foreign Patent Documen	t	Name of Detector on Applicant	Date of Publication of
Examiner Initials*	Cite No.	Office	e Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		EP	0 464 287 A1		The Research Foundation for Microbial Diseases of Osaka University	12/28/1990
		EP	0 463 848 A2		The Research Foundation for Microbial Diseases of Osaka University	06/25/1991
		wo	95/22985		Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	08/31/1995
		wo	94/05809		Fox Chase Cancer Center	03/17/1994
1						

Examiner Signature	 Date Considered	

COMPLE KNOWN Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor De Francesco et al. Group Art Unit (use as many sheets as necessary) Examiner Name 2 2 Sheet of IT0002PCA Attorney Docket Number

	-	OTHER NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Al et al., Expression and characterization of the NS5B (RNA-dependent RNA polymerase) gene of hepatitis C virus, Hepatology, Vol. 22, No. 4 Pt. 2, pp 331A, 1995.
		Tomei et al., NS3 is a serine protease required for processing of hepatitis C virus polyprotein, J. of Virology, Vol. 67, No. 7, pps 4017-4026, 1993.
		Bartenschlager et al., Kinetic and structural analyses of hepatitis C virus polyprotein processing, J. of Virology, Vol. 68, No. 8, pps 5045-5055, 1994.
		Lin et al., Hepatitis C virus NS3 serine proteinase trans-cleavage requirements and processing kinetics, J. of Virology, Vol. 68, No. 12, pps 8147-8157, 1994.
		Miller et al., Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups, Proc. Natl. Acad. Sci. USA, Vol. 87, pps 2057-2061, 1990.
		Behrens et al., Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus, The EMBO Journal, Vol. 15, No. 1, pps 12-22, 1996.
		Bartholomeusz et al., Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds, Antiviral Research, Vol. 24, pps 341-350, 1994.
		Grun et al., Dissociation of NS5 from cell fractions containing west nile virus-specific polymerase activity, Journal of Virology, Vol. 61, No. 11, pps 3641-3644, 1987.
		Chu et al., Characterization of kunjin virus RNA-dependent RNA polymerase: reinitiation of synthesis in vitro, Virology, Vol. 157, pps 330-337, 1987.
		Grun et al., Characterization of west nile virus RNA-dependent RNA polymerase and cellular terminal adenylyl and uridylyl transferase in cell-free extracts, Journal of Virology, Vol. 60, No. 3, pps 1113-1124, 1986.
		Bartholomeusz et al., Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5, Arch Virol, Vol. 128, pps 111-121, 1993.
		Lohmann et al., Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity, Journal of Virology, Vol. 71, No. 11, pps 8416-8428, 1997.

Carmina	Data	1
Examiner	Date	1
Cimmatum	Camaidanad	l .
Signature	Considered	l .

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.